Marshall Dennis E 4

What Happened

• Dennis E. Marshall, a director of BIOLARGO, received two derivative awards (grants) on June 30, 2026 totaling 313,979 shares: 198,238 and 115,741 shares. The Form 4 lists these as grants (code A) and reports the derivative figures; per the filing the share/option exercise price is not shown in the table (N/A). The filing was submitted to the SEC on July 2, 2026.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02 (no late filing indicated).
• Awards: 198,238 and 115,741 share-equivalents (total 313,979).
• Price: exercise/strike price not disclosed in the table (reported as N/A).
• Shares owned after the transaction: not reported in the provided summary.
• Footnotes of note:
  • F1: One option was granted to replace an option to purchase 22,500 shares that expired unexercised due to an exercise-price discrepancy (replacement approved by the Compensation Committee).
  • F2: Confirms expiration of the prior options to purchase 22,500 shares on June 30, 2026.
  • F3: One option was issued as payment for $18,750 in board fees under the 2024 Equity Incentive Plan; the option share count equals fees divided by the option exercise price.

Context

• These were grants of derivative awards (options/award units), not open-market purchases — they do not represent an immediate outlay of the insider's personal cash to buy common shares nor an immediate sale. The grants replace expired options and compensate board services; actual ownership of common stock would occur only if/when options are exercised and any vesting conditions are met. For retail investors, such awards are routine compensation and should be interpreted differently than direct purchases or sales.